BridgeBio Pharma (NASDAQ:BBIO) Azioni

BRIDGEBIO PHARMA INC

BridgeBio Pharma

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BBIO

ISRG

ITCI

Anticipazioni di mercato rivelano titoli sanitari in crisi: azioni ad alto rischio da valutare per una potenziale vendita immediata.

Questi 4 titoli del settore sanitario potrebbero scoppiare: vendere subito?

BridgeBio Pharma Inc

WIIM

Synovus shares are trading higher after a report suggesting the company is weighing a potential merger following takeover interest.

<a href="https://www.bloomberg.com/news/articles/2025-07-22/synovus-weighs-potential-merger-after-drawing-takeover-interest?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-07-22/synovus-weighs-potential-merger-after-drawing-takeover-interest?srnd=homepage-americas</a>

General

'Synovus Weighs Potential Merger After Drawing Takeover Interest'- Bloomberg

Core Natural Resources shares are trading higher. B. Riley Securities maintained a Buy rating on the stock.

Warrior Met Coal shares are trading higher. B. Riley Securities maintained a Buy rating on the stock.

TIGR

UP Fintech Holdings shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $9.5 to $14.

CYRX

CryoPort shares are trading higher after Stephens & Co. assumed an Overweight rating on the stock and announced a price target of $13.

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K.
The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">both respiratory viruses</a>, and expands the capabilities in vaccine design and development with Vicebio&#8217;s &#8216;Molecular Clamp&#8217; technology.
The vaccine candidate complements Sanofi&#8217;s position in the respiratory vaccines space, where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient choice in RSV and hMPV by adding a non-mRNA vaccine to its pipeline.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46423319/gsk-seeks-fda-nod-to-broaden-rsv-vaccine-for-younger-at-risk-adults" rel="noreferrer noopener">GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults</a>
The acquisition also adds &#8216;Molecular Clamp,&#8217; a technology stabilizing viral proteins in their native shape, enabling the immune system to recognize and respond to them more effectively.
The approach enables quicker development of fully liquid combination vaccines stored at standard refrigeration temperatures (2–8°C), eliminating the need for freezing or freeze-drying, thereby simplifying manufacturing and distribution.
Furthermore, fully liquid vaccines can be made available in prefilled syringes, enhancing ease of use, safety, and operational efficiency across healthcare settings.&nbsp;
Under the terms of the agreement, Sanofi would <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-22-05-30-00-3119150" rel="noreferrer noopener">acquire</a> all of Vicebio&#8217;s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements.
The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals. The acquisition will not have a significant impact on Sanofi&#8217;s financial guidance for 2025.
Vicebio&#8217;s pipeline includes VXB-241, a bivalent vaccine candidate targeting RSV and hMPV, currently in an exploratory phase 1 study in older adults, and VXB-251, a preclinical trivalent vaccine candidate targeting RSV, hMPV, and parainfluenza virus Type 3 (PIV3).
This acquisition reinforces Sanofi&#8217;s commitment to innovation in respiratory vaccines. In June, Sanofi said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 RSV season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45839621/beyfortus-output-tripled-as-sanofi-astrazeneca-scale-up-for-rsv-season" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
This acquisition follows another significant move by Sanofi in June 2025, when it agreed to acquire Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) for <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45719179/sanofi-expands-rare-immunology-portfolio-with-blueprint-buyout" rel="noreferrer noopener">approximately $9.1 billion</a>.
That acquisition included Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the U.S. and the EU, along with a promising advanced and early-stage immunology pipeline.
Price Action: SNY stock is trading higher by 1.42% to $48.61 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46551879/ai-bubble-is-more-unhinged-than-dot-com-a-chilling-warning-from-the-inside" target="_blank" rel="noreferrer noopener">AI Bubble Is More Unhinged Than Dot-Com—A Chilling Warning From The Inside</a></li>
</ul>
Photo by HJBC via Shutterstock

Biotech

Large Cap

Health Care

Movers

BPMC

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) unit PNC Bank and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) announced on Tuesday a strategic alliance to broaden secure cryptocurrency offerings and extend banking services for<a href="https://www.benzinga.com/pressreleases/25/07/n46545762/pnc-bank-coinbase-announce-strategic-partnership-to-advance-digital-asset-solutions-and-expand-ban" target="_blank" rel="noreferrer noopener"> retail and institutional clients.</a>
Under the agreement, PNC Bank will integrate Coinbase&#8217;s Crypto‑as‑a‑Service platform to enable customers to buy, hold and sell digital assets, while also delivering tailored banking solutions to Coinbase itself.
The partnership combines PNC&#8217;s longstanding client service expertise with Coinbase&#8217;s institutional‑grade infrastructure, giving users seamless, secure access to cryptocurrency markets.
Also Read:<a target="_blank" href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46543876/jamie-dimon-once-called-bitcoin-a-fraud-now-jpmorgan-might-lend-against-it" rel="noreferrer noopener"> Jamie Dimon Once Called Bitcoin A &#8216;Fraud&#8217;—Now JPMorgan Might Lend Against It</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PNC stock has gained over 11% in the past year. Investors can gain exposure to the stock via&nbsp;iShares U.S. Regional Banks ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAT#NYSE">IAT</a>).
As part of the deal, PNC Bank will provide deposit accounts, treasury management and other core financial products to support Coinbase&#8217;s growth and strengthen system resiliency.
By uniting PNC&#8217;s banking network with Coinbase&#8217;s digital asset capabilities, the collaboration aims to foster a more resilient, innovative financial ecosystem.
&#8220;Partnering with Coinbase accelerates our ability to bring innovative, crypto financial solutions to our clients,&#8221; said William S. Demchak, PNC chairman and CEO.
Brett Tejpaul, head of&nbsp;Coinbase&nbsp;Institutional, said, &#8220;PNC is a market leader in delivering best-in-class products for their clients.&#8221;
&#8220;We&#8217;re thrilled to support their entry into the digital asset market with our leading&nbsp;Crypto&nbsp;as a Service platform, which provides PNC with a powerful set of tools to develop a scalable, high-growth business, built on a foundation of uncompromising security,&#8221; Tejpaul added.
COIN stock has gained over 51% in the past year. Investors can gain exposure to the stock via First Trust SkyBridge Crypto Industry and Digital Economy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRPT#NYSE">CRPT</a>).
PNC, COIN Price Actions: PNC Financial Services Group shares are trading higher by 1.15% to $198.31; Coinbase was down 1.75% at $406.47 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/07/46535957/ethereum-roars-to-3-800-whats-driving-the-surge" target="_blank" rel="noreferrer noopener">Ethereum Roars To $3,800: What's Driving The Surge?</a></li>
</ul>
Photo: PNC, courtesy PNC; Coinbase via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Fintech news covering the emerging Financial Technology services sector

Fintech

COIN

CRPT

iShares Dow Jones US Regional Banks Index Fund

PNC, Coinbase Partnership Aims To Revolutionize Crypto Banking Infrastructure

Needham analyst Quinn Bolton maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Buy and raises the price target from $225 to $250.

Price Target

Analyst Ratings

NXPI

Needham Maintains Buy on NXP Semiconductors, Raises Price Target to $250

Jefferies analyst Roger Song maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and lowers the price target from $31 to $6.

REPL

Jefferies Maintains Buy on Replimune Group, Lowers Price Target to $6

Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)&nbsp;on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.84 billion</a>.&nbsp;
The life science giant reported adjusted earnings of $1.80 per share, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538741/danaher-reports-second-quarter-2025-results" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">low single digits</a> year over year.
Operating cash flow was $1.3 billion, and non-GAAP&nbsp;free cash flow was $1.1 billion.
Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
Biotechnology&nbsp;<a target="_blank" href="https://filecache.investorroom.com/mr5ir_danaher/934/Q2%202025%20Danaher%20Earnings%20Presentation.pdf" rel="noreferrer noopener">sales</a> increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%.
Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion.
The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations."
<h2 class="wp-block-heading">Guidance</h2>
Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives.
Danaher&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Earnings+Supplement.pdf" rel="noreferrer noopener">reaffirms</a> that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year.
Cepheid 2025 respiratory revenues will be around&nbsp;$1.7 billion.
The company expects an adjusted operating profit margin of around 25.5%.
Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025.
Life sciences core revenue will remain flat for the third quarter and fiscal year 2025.
Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025.
<h2 class="wp-block-heading">Management update</h2>
Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning &amp; Analysis, will succeed Matthew McGrew as Danaher's CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538769/danaher-announces-transition-plan-for-chief-financial-officer" rel="noreferrer noopener">effective February 28, 2026</a>.
<h2 class="wp-block-heading">Analyst Opinion</h2>
William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment."
Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains<a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener"> the Outperform rating</a>.
Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46548132/marlboro-parent-philip-morris-internationals-smoke-free-segment-powers-q2-gains" target="_blank" rel="noreferrer noopener">Marlboro Parent Philip Morris International's Smoke-Free Segment Powers Q2 Gains</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Guidance

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

Interpublic Group Launches Agentic Systems For Commerce To Help Brands Manage Scaled And Complex Commerce Ecosystem With Automation And AI

CIBC analyst Hamir Patel maintains West Fraser Timber (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WFG#TSX">WFG</a>) with a Outperformer and lowers the price target from C$142 to C$122.

TSX:WFG

CIBC Maintains Outperformer on West Fraser Timber, Lowers Price Target to C$122

CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) will release its quarterly earnings report on Wednesday, 2025-07-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate CVB Financial to report an earnings per share (EPS) of $0.35.
CVB Financial bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 0.69% increase in the share price on the subsequent day.
Here's a look at CVB Financial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.33</td>
<td>0.34</td>
<td>0.34</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.36</td>
<td>0.37</td>
<td>0.36</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-0.0%</td>
<td>3.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207406_0.png" alt="eps graph" />
<h3>Performance of CVB Financial Shares</h3>
Shares of CVB Financial were trading at $20.82 as of July 21. Over the last 52-week period, shares are up 7.46%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CVBF/earnings">To track all earnings releases for CVB Financial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVBF

A Look Ahead: CVB Financial's Earnings Forecast

Roth Capital analyst Chip Moore maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Neutral and raises the price target from $122 to $140.

GNRC

Roth Capital Maintains Neutral on Generac Hldgs, Raises Price Target to $140

Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-23. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Popular will report an earnings per share (EPS) of $2.58.
Popular bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.38, leading to a 1.21% increase in the share price the following trading session.
Here's a look at Popular's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.18</td>
<td>2.10</td>
<td>2.31</td>
<td>2.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.56</td>
<td>2.51</td>
<td>2.16</td>
<td>2.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207391_0.png" alt="eps graph" />
<h3>Tracking Popular's Stock Performance</h3>
Shares of Popular were trading at $114.99 as of July 21. Over the last 52-week period, shares are up 16.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BPOP/earnings">To track all earnings releases for Popular visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPOP

Insights Ahead: Popular's Quarterly Earnings

United Community Banks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCB#NYSE">UCB</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect United Community Banks to report an earnings per share (EPS) of $0.61.
The market awaits United Community Banks's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.03 in the last quarter, leading to a 1.37% increase in the share price on the following day.
Here's a look at United Community Banks's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.56</td>
<td>0.57</td>
<td>0.51</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.59</td>
<td>0.63</td>
<td>0.57</td>
<td>0.58</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207378_0.png" alt="eps graph" />
<h3>Tracking United Community Banks's Stock Performance</h3>
Shares of United Community Banks were trading at $31.43 as of July 21. Over the last 52-week period, shares are up 4.29%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/UCB/earnings">To track all earnings releases for United Community Banks visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at United Community Banks's Upcoming Earnings Report

Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-23. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Knight-Swift will report an earnings per share (EPS) of $0.33.
The market awaits Knight-Swift's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 1.94% increase in the share price the following trading session.
Here's a look at Knight-Swift's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.24</td>
<td>0.33</td>
<td>0.32</td>
<td>0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.28</td>
<td>0.36</td>
<td>0.34</td>
<td>0.24</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>5.0%</td>
<td>-2.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207368_0.png" alt="eps graph" />
<h3>Performance of Knight-Swift Shares</h3>
Shares of Knight-Swift were trading at $44.43 as of July 21. Over the last 52-week period, shares are down 7.64%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Knight-Swift</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Knight-Swift.
With 16 analyst ratings, Knight-Swift has a consensus rating of Outperform. The average one-year price target is $51.25, indicating a potential 15.35% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Ryder System, Saia and Landstar System, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Ryder System, with an average 1-year price target of $179.83, suggesting a potential 304.75% upside.</li>
<li>Analysts currently favor an Buy trajectory for Saia, with an average 1-year price target of $314.18, suggesting a potential 607.13% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Landstar System, with an average 1-year price target of $140.71, suggesting a potential 216.7% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for Ryder System, Saia and Landstar System, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knight-Swift</td>
<td>Outperform</td>
<td>0.10%</td>
<td>$246.20M</td>
<td>0.43%</td>
</tr>
<tr>
<td>Ryder System</td>
<td>Neutral</td>
<td>0.71%</td>
<td>$616M</td>
<td>3.20%</td>
</tr>
<tr>
<td>Saia</td>
<td>Buy</td>
<td>4.35%</td>
<td>$112.76M</td>
<td>2.13%</td>
</tr>
<tr>
<td>Landstar System</td>
<td>Neutral</td>
<td>-1.58%</td>
<td>$149.08M</td>
<td>3.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Knight-Swift ranks at the top for Revenue Growth with a modest increase. It is at the bottom for Gross Profit, indicating lower profitability. Knight-Swift is at the bottom for Return on Equity, suggesting lower returns for shareholders. Overall, Knight-Swift's performance is mixed compared to its peers.
<h3>Unveiling the Story Behind Knight-Swift</h3>
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.
<h3>Knight-Swift: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Knight-Swift displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 0.1%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Knight-Swift's net margin is impressive, surpassing industry averages. With a net margin of 1.68%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Knight-Swift's ROE stands out, surpassing industry averages. With an impressive ROE of 0.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Knight-Swift's ROA excels beyond industry benchmarks, reaching 0.24%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.45, Knight-Swift adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/KNX/earnings">To track all earnings releases for Knight-Swift visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Knight-Swift's Earnings: A Preview

Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Alaska Air Gr to report an earnings per share (EPS) of $1.55.
Alaska Air Gr bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 9.98% drop in the share price the next day.
Here's a look at Alaska Air Gr's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.77</td>
<td>0.36</td>
<td>1.96</td>
<td>2.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.77</td>
<td>0.97</td>
<td>2.25</td>
<td>2.55</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>2.0%</td>
<td>3.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207358_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Alaska Air Gr were trading at $52.61 as of July 21. Over the last 52-week period, shares are up 39.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Alaska Air Gr</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Alaska Air Gr.
The consensus rating for Alaska Air Gr is Outperform, based on 3 analyst ratings. With an average one-year price target of $54.67, there's a potential 3.92% upside.
<h3>Peer Ratings Overview</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of JetBlue Airways, Frontier Group Holdings and Allegiant Travel, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for JetBlue Airways, with an average 1-year price target of $4.0, suggesting a potential 92.4% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Frontier Group Holdings, with an average 1-year price target of $5.67, suggesting a potential 89.22% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $67.38, suggesting a potential 28.07% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
In the peer analysis summary, key metrics for JetBlue Airways, Frontier Group Holdings and Allegiant Travel are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska Air Gr</td>
<td>Outperform</td>
<td>40.55%</td>
<td>$255M</td>
<td>-3.90%</td>
</tr>
<tr>
<td>JetBlue Airways</td>
<td>Neutral</td>
<td>-3.12%</td>
<td>$229M</td>
<td>-8.18%</td>
</tr>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>5.43%</td>
<td>$13M</td>
<td>-7.33%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>6.50%</td>
<td>$123.71M</td>
<td>2.84%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Alaska Air Gr ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it has the lowest Return on Equity.
<h3>About Alaska Air Gr</h3>
Alaska Air Group Inc operates two airlines, Alaska and Horizon in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico, and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements (CPA). The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary and Mileage Plan passenger revenue.
<h3>Alaska Air Gr's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Alaska Air Gr's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 40.55%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Alaska Air Gr's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Alaska Air Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -3.9%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Alaska Air Gr's ROA excels beyond industry benchmarks, reaching -0.84%. This signifies efficient management of assets and strong financial health.
Debt Management: Alaska Air Gr's debt-to-equity ratio is below the industry average. With a ratio of 1.52, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ALK/earnings">To track all earnings releases for Alaska Air Gr visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alaska Air Gr's Earnings Outlook

West Fraser Timber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFG#NYSE">WFG</a>) will release its quarterly earnings report on Wednesday, 2025-07-23. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate West Fraser Timber to report an earnings per share (EPS) of $0.93.
Investors in West Fraser Timber are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.15, which was followed by a 2.27% drop in the share price the next day.
Here's a look at West Fraser Timber's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.61</td>
<td>0.06</td>
<td>-0.50</td>
<td>1.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.46</td>
<td>0.10</td>
<td>-1.03</td>
<td>1.20</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753207344_0.png" alt="eps graph" />
<h3>Tracking West Fraser Timber's Stock Performance</h3>
Shares of West Fraser Timber were trading at $72.54 as of July 21. Over the last 52-week period, shares are down 5.9%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/WFG/earnings">To track all earnings releases for West Fraser Timber visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: West Fraser Timber

Press Releases

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types

Comments

BridgeBio Pharma

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO